Orphan drugs: Unmet societal need for non-profitable privately supplied new products

por Moors, Ellen H.M., Faber, Jan
Publicado 2007

From Mattering to Mattering More: ‘Goods’ and ‘Bads’ in Ageing and Innovation Policy Discourses

por Greubel, Carla, Moors, Ellen H. M., Peine, Alexander
Publicado 2021

Market Formation in a Global Health Transition

por de Haan, Freek, Moors, Ellen H.M., Dondorp, Arjen M., Boon, Wouter P.C.
Publicado 2021

Implementation of artificial intelligence (AI) applications in radiology: hindering and facilitating factors

por Strohm, Lea, Hehakaya, Charisma, Ranschaert, Erik R., Boon, Wouter P. C., Moors, Ellen H. M.
Publicado 2020

Levelling the Translational Gap for Animal to Human Efficacy Data

por Ferreira, Guilherme S., Veening-Griffioen, Désirée H., Boon, Wouter P. C., Moors, Ellen H. M., van Meer, Peter J. K.
Publicado 2020

The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals

por Ebbers, Hans C., Mantel-Teeuwisse, Aukje K., Sayed-Tabatabaei, Fakhredin A., Moors, Ellen H. M., Schellekens, Huub, Leufkens, Hubert G. M.
Publicado 2012

Problems and Promises of Introducing the Magnetic Resonance Imaging Linear Accelerator Into Routine Care: The Case of Prostate Cancer

por Hehakaya, Charisma, Van der Voort van Zyp, Jochem R., Lagendijk, Jan J. W., Grobbee, Diederick E., Verkooijen, Helena M., Moors, Ellen H. M.
Publicado 2020

Exploring the feasibility of introducing triple artemisinin-based combination therapy in the malaria treatment policy in Vietnam

por Cao, Van Anh Thi, Nguyen, Thieu Quang, Le Quyen, Duong, Boon, Wouter P. C., Moors, Ellen H. M., Dondorp, Arjen M., de Haan, Freek, Amaratunga, Chanaki
Publicado 2023

A standardised framework to identify optimal animal models for efficacy assessment in drug development

por S. Ferreira, Guilherme, Veening-Griffioen, Désirée H., Boon, Wouter P. C., Moors, Ellen H. M., Gispen-de Wied, Christine C., Schellekens, Huub, van Meer, Peter J. K.
Publicado 2019

Correction: A standardised framework to identify optimal animal models for efficacy assessment in drug development

por Ferreira, Guilherme S., Veening-Griffioen, Désirée H., Boon, Wouter P. C., Moors, Ellen H. M., Gispen-de Wied, Christine C., Schellekens, Huub, van Meer, Peter J. K.
Publicado 2019

Implementation of Magnetic Resonance Imaging-Guided Radiation Therapy in Routine Care: Opportunities and Challenges in the United States

por Hehakaya, Charisma, Sharma, Ankur M., van der Voort Van Zijp, Jochem R.N., Grobbee, Diederick E., Verkooijen, Helena M., Izaguirre, Enrique W., Moors, Ellen H.M.
Publicado 2022

Toward Responsible Artificial Intelligence in Long-Term Care: A Scoping Review on Practical Approaches

por Lukkien, Dirk R M, Nap, Henk Herman, Buimer, Hendrik P, Peine, Alexander, Boon, Wouter P C, Ket, Johannes C F, Minkman, Mirella M N, Moors, Ellen H M
Publicado 2021

Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion

por de Haan, Freek, Amaratunga, Chanaki, Thi, Van Anh Cao, Orng, Long Heng, Vonglokham, Manithong, Quang, Thieu Nguyen, Lek, Dysoley, Boon, Wouter P. C., Dondorp, Arjen M., Moors, Ellen H. M.
Publicado 2023

Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs

por Ferreira, Guilherme S., Dijkstra, Francis M., Veening-Griffioen, Désirée H., Boon, Wouter P. C., Schellekens, Huub, Moors, Ellen H. M., van Meer, Peter J. K., Stuurman, Frederik E., van Gerven, Joop M. A.
Publicado 2023

The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso

por Guissou, Rosemonde M., Amaratunga, Chanaki, de Haan, Freek, Tou, Fatoumata, Cheah, Phaik Yeong, Yerbanga, R. Serge, Moors, Ellen H. M., Dhorda, Mehul, Tindana, Paulina, Boon, Wouter P. C., Dondorp, Arjen M., Ouédraogo, Jean Bosco
Publicado 2023

Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.

por Tindana, Paulina, de Haan, Freek, Mokuolu, Olugbenga Ayodeji, Guissou, Rosemonde, Bolarinwa, Oladimeji Akeem, Ouedraogo, Jean Bosco, Tou, Fatoumata, Boon, Wouter P.C, Moors, Ellen H.M, Dondorp, Arjen M, Dhorda, Mehul, Amaratunga, Chanaki, Cheah, Phaik Yeong
Publicado 2021

To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?

por de Haan, Freek, Bolarinwa, Oladimeji Akeem, Guissou, Rosemonde, Tou, Fatoumata, Tindana, Paulina, Boon, Wouter P. C., Moors, Ellen H. M., Cheah, Phaik Yeong, Dhorda, Mehul, Dondorp, Arjen M., Ouedraogo, Jean Bosco, Mokuolu, Olugbenga A., Amaratunga, Chanaki
Publicado 2021